GGrantIndex
← Search

Genome Editing and Animal Models

$39,393P30FY2023CANIH

University Of Wisconsin-Madison, Madison WI

Investigators

Linked publications, trials & patents

Paper 39638850Paper 39604703Paper 39580301Paper 39530524Paper 39527745Paper 39516197Paper 39484544Paper 39481346Paper 39474803Paper 39462136Paper 39452931Paper 39444276Paper 39443360Paper 39432401Paper 39414902Paper 39408582Paper 39407431Paper 39402986Paper 39399121Paper 39386576Paper 39386545Paper 39379374Paper 39374311Paper 39364328Paper 39358429Paper 39345631Paper 39335130Paper 39312186Trial NCT06608511Trial NCT06557733Trial NCT05985681Trial NCT05521698Trial NCT05107219Trial NCT03725761Trial NCT03722030Trial NCT03703492Trial NCT03656276Trial NCT03393741Trial NCT03387514Trial NCT03358563Trial NCT03356470Trial NCT03342378Trial NCT03304002Trial NCT03300557Trial NCT03209869Trial NCT03185871Trial NCT03028584Trial NCT03023202Trial NCT02955043Trial NCT02917629Trial NCT02876640Trial NCT02780401Trial NCT02719821Trial NCT02169284Trial NCT02096783Trial NCT02095145Trial NCT01999881Trial NCT01935960Trial NCT01901835Trial NCT01707004Trial NCT01625156Trial NCT01325311Trial NCT01263613Trial NCT01245205Trial NCT01243359Trial NCT01233505Trial NCT01218620Trial NCT01217450Trial NCT01158274Trial NCT01083641Trial NCT01004796Trial NCT00896974Trial NCT00666562Trial NCT00544596Trial NCT00499135Trial NCT00462969Trial NCT00415025Trial NCT00410605Trial NCT00227513Trial NCT00138203Trial NCT00109863Trial NCT00079014Trial NCT00052832Trial NCT00049712Trial NCT00036790Trial NCT00028652Trial NCT00023855Trial NCT00022412Trial NCT00005794Trial NCT00004872Patent 9867974Patent 9763597Patent 9603567Patent 9470697Patent 9161720Patent 8871458Patent 6974254Patent 6438202Patent 6114119Patent 6020178

Abstract

PROJECT SUMMARY / ABSTRACT Genetically engineered animals and cell lines are widely used as models to define the mechanisms underlying cancer etiology and progression and to evaluate strategies for cancer treatment and prevention. The Genome Editing and Animal Models Shared Resource (GEAM) has served as a shared resource for the University of Wisconsin Carbone Cancer Center (UWCCC) for over three decades and is one of the elite facilities in the United States to offer the comprehensive services required to generate, characterize, and preserve genome edited animal models. GEAM’s mission is to make state-of-the-art genome editing technologies for animals and cell lines as well as cryopreservation services accessible to UWCCC members. Specific Aim 1 is to generate novel, highly relevant, genome edited or transgenic animal models of human cancers. GEAM staff serve UWCCC members in all aspects of experiment planning, including the design of efficient approaches to achieve the desired genome manipulation using CRISPR, homologous recombination, and transgene-based approaches; the identification of animals that carry the desired genome edit or transgene; and the minimization of off target edits. Our extensive experience in reproductive biology, embryo manipulation, and animal husbandry enable GEAM to edit the genomes of mouse and rat strains that exhibit low reproductive capacity. Specific Aim 2 is to develop clonally derived, genome edited, cell lines for use in cancer research. In the current cycle, GEAM established a pipeline that is capable of editing the genome of a wide variety of established cell lines and implemented a state-of-the-art automated clone tracking system. Specific Aim 3 is to provide state-of-the-art reproductive biology services that enable animal model banking, recovery, and sharing. GEAM’s sperm and embryo cryopreservation capabilities reduce animal husbandry costs and allow recovery of cancer models through embryo transfer or in vitro fertilization. Rederivation of rodent models eliminates pathogens that may compromise research or prevent animal model importation into campus vivaria or sharing between collaborators. In the current cycle, GEAM has continued to modernize our infrastructure through purchases of new equipment using institutional support, adopted the latest and most advanced genome editing methods, and added highly trained staff to best meet the increasing and technically challenging needs of our users. Thirty-nine unique UWCCC program members were served by GEAM during the current Cancer Center Support Grant (CCSG) funding cycle. Support from the CCSG enables GEAM’s services to be tailored to the unique needs of UWCCC members and provided at costs below those of commercial vendors or similar cores at other research universities. GEAM’s first rate, cost effective, services enhance the ability of UWCCC investigators to conduct innovative research and advance the strategic mission of the Center. Data from biennial surveys of UWCCC members indicate GEAM’s services are high quality and critical to our members’ research.

View original record on NIH RePORTER →